Minerva Neurosciences, Inc.

Dedicated to transforming the lives of people affected by neuropsychiatric diseases through innovative science that addresses patients' unmet needs.

About Us

Dedicated to transforming lives



Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe contain innovative mechanisms of action. As we work to advance our current product pipeline, we plan to explore additional indications identify new product candidates from our existing intellectual property, and acquire rights to additional promising product candidates with significant therapeutic potential. Our executive management team includes globally recognized specialists in neuropsychiatric disease and commercialization of products addressing significant unmet medical needs.

Our strategy is based on four key principles: unwavering commitment to neuropsychiatric patients, their families and communities; scientific rigor; continually leveraging patient and caregiver insights to drive scientific advancement; and an unparalleled commitment to integrity in all of our business dealings. As we work to advance our pipeline of products through clinical development and regulatory review, we may also selectively explore collaborations with leading pharmaceutical companies.

Leadership

Management Team


Remy Luthringer, PhD

Remy Luthringer, PhD

President and Chief Executive Officer

Dr. Remy Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.

Geoff Race, FCMA, MBA

Geoff Race, FCMA, MBA

Executive Vice President and
Chief Financial Officer

Prior to being named as Minerva Neurosciences' CFO, Mr. Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012. He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.

Joseph Reilly

Joseph Reilly

Vice President and Chief Operating Officer

Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation. In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.

Fred Ahlholm

Fred Ahlholm

Vice President and Chief Accounting Officer

Fred Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. Fred is a CPA and earned his BBA at the University of Notre Dame.

Mark Levine

Mark Levine

Vice President and General Counsel

Mark Levine has extensive experience counseling companies on general corporate matters, complex commercial transactions, mergers and acquisitions, securities law, corporate governance and regulatory compliance. Prior to joining Minerva Neurosciences in 2014, he served in senior legal positions at athenahealth, Inc., Clinical Data, Inc., Wheelabrator Technologies Inc., and Xpedior Incorporated. He holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.

Board of Directors

Marc Beer

Chairman of the Board, Aegerion Pharmaceuticals

Remy Luthringer, PhD

President and Chief Executive Officer

Jan Van Heek

Chair of Audit Committee, Amarin

Francesco De Rubertis, PhD

Director, Index Ventures

Michele Ollier, MD

Director, Index Ventures

Nico Vandervelpen

Chief Operating Officer, LRM

Science

Targeting a range of unmet needs in neuropsychiatry


Minerva Neurosciences is focused on the field of neuropsychiatry within the central nervous system (CNS) disease pharmaceutical market. Neuropsychiatry is a medical subspecialty devoted to understanding cognitive, emotional, behavioral, and perceptual symptoms resulting from circuit-specific brain dysfunction and includes a range of serious diseases and conditions. Our pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease, each of which affects millions of people around the world. Currently available treatment options for these conditions are known to have significant limitations that can often result in high rates of discontinuation of therapy and unsatisfactory efficacy and safety profiles. Family members also often face significant challenges associated with the burden of these and many other neuropsychiatric diseases. We are pursuing the development of new therapeutic options based on its deep knowledge of the pathology of neuropsychiatric diseases, the pharmacology of its library of compounds and its understanding of desired outcomes for unmet patient needs. We believe our product candidates each have novel mechanisms of action and represent differentiated treatment options with the potential to address significant unmet needs with improved efficacy and safety.

Minerva's Pipeline

We currently have a portfolio of first-in-class product candidates in the pipeline: MIN-101, MIN-117, MIN-202 and MIN-301.

Pipeline of Next Generation Neuropsychiatry Pharmaceuticals

Program Primary
Indication
Phase 1 Phase 2 Rights
1) BA = Bioavailability 2) HV = Healthy Volunteers 3) MAD = Multiple ascending dose
MIN-101 Schizophrenia
  • 6 trials completed
  • Once a day formulation ongoing
  • Phase 2a completed
  • Phase 2b to be submitted Q414
Global ex-Asia
MIN-117 Major depressive disorder (MDD)
  • 2 trials completed
  • Phase 2 studies planning ongoing
Global ex-Asia
MIN-202 Insomnia
  • Phase 1b in MDD ongoing
  • BA1 study in HV2 ongoing
  • MAD3 study in HV ongoing
European Union
MIN-301 Parkinson's disease
  • Preclinical studies ongoing
Global

MIN-101 FOR THE TREATMENT OF SCHIZOPHRENIA

Patients suffering with schizophrenia present with (1) positive symptoms, such as delusions, hallucinations, thought disorders, and agitation, (2) negative symptoms, such as mood flatness and lack of pleasure in daily life, (3) cognitive symptoms, such as the decreased ability to understand information and make decisions, difficulty focusing, and decreased working memory function, and (4) sleep disorders. Our lead product candidate, MIN-101, is an innovative molecule behaving as an antagonist on 5-HT2A and sigma-2 receptors. It is in development for the treatment of patients affected by schizophrenia and, in particular, those suffering from negative symptoms of the disease.

Most currently approved therapies for schizophrenia show efficacy primarily in the management of positive symptoms. As a result, patients with predominantly negative symptoms are often underserved. Side effects of current pharmaceutical treatment options include sedation, uncontrollable muscle movements, weight gain, cognitive impairment, and sleep disorders. Due to its particular pharmacologic profile, MIN-101 has the potential to address negative and cognitive symptoms and improve sleep while addressing overall symptoms of schizophrenia for patients in treatment as well as for treatment-naive patients, all with an improved side effect profile compared to the current standard of care. In a Phase IIA, placebo-controlled trial, clinically significant improvement of negative symptoms and a trend toward the improvement of positive and cognitive symptoms and overall psychopathology was observed after three months of drug administration. We hold the exclusive license for this molecule from Mitsubishi Tanabe Pharma Corporation.

MIN-117 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

M117 is an innovative molecule behaving as an antagonist on 5-HT1A and 5-HTT receptors and both serotonin and dopamine reuptake. It is in development for the treatment of MDD, a mood disorder in which feelings of sadness, loss, anger or frustration interfere with a person's ability to carry out and enjoy once-pleasurable activities. Current therapies are linked with several side effects, including, among others, sleep problems, headache, anxiety or restlessness, cognitive impairments, weight gain and sexual dysfunction. Further, due to their mechanisms of action, some current treatment options take up to four weeks to have a noticeable effect, which can expose patients to a period of vulnerability and suicide risk.

Two Phase I clinical trials have confirmed the safety and tolerability profile of MIN-117 and the potential for once-a-day administration. Further, the effects on sleep of MIN-117 in the Phase I clinical trials indicate a potential onset of action in MDD patients within just a few days. We hold the exclusive license for this molecule from Mitsubishi Tanabe Pharma Corporation.

MIN-202 FOR THE TREATMENT OF INSOMNIA

MIN-202 is an innovative molecule acting as a selective orexin-2 receptor antagonist for the treatment of primary and secondary insomnia. The major drawbacks of current insomnia medications are that immediate-onset therapies taken at bedtime can interfere with natural sleep onset and deep sleep patterns. As a result, patients can experience residual effects the following day, such as daytime sedation, slowed or distorted reaction-time, and cognitive impairment. We believe MIN-202 is an advanced compound that targets the action of wakefulness-promoting neurons, which we believe is likely to result in better safety and tolerability and preservation of physiologic and restorative sleep. We are jointly developing MIN-202 under a co-development and license agreement with Janssen Pharmaceutica N.V., a Johnson & Johnson company.

MIN-301 FOR THE TREATMENT OF PARKINSON'S DISEASE

MIN-301 is a recombinant form of the neuregulin-1β1 peptide and is currently in preclinical development for the treatment of Parkinson's disease. Current treatments for Parkinson's disease have been shown to improve symptoms for many patients, but they have not been proven to delay the onset of disease, slow or prevent disease progression, or reverse its effects. Research involving multiple preclinical models mimicking Parkinson's disease symptoms has been carried out with MIN-301. The results obtained thus far show that the peptide has the potential to restore motor function distorted in Parkinson's patients, with a positive effect on cognition. We own the rights globally to the MIN-301 peptide.

Investors and Media

The Minerva Neurosciences team is focused on its commitment to deliver long-term value to investors through solid business planning and execution.
Visit Site

Contact

Minerva Neurosciences, Inc.

1601 Trapelo Road, Suite 284
Waltham, MA 02451
617.600.7373
For general inquiries, please contact:
info@minervaneurosciences.com

For media inquiries, please contact:
Bill Berry
Berry & Company Public Relations
212.253.8881
bberry@berrypr.com

For investor inquiries, please contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com



© Copyright 2014 Minerva Neurosciences Inc., All Rights Reserved
Privacy Policy | Terms of Use